Novo Nordisk's (NVO) investigational once-weekly weight-loss and diabetes treatment CagriSema was superior to tirzepatide and met its primary superiority endpoint in two phase 3 trials, respectively, the company said Monday.

In one study, CagriSema achieved an average weight loss of 12.4%, compared with 9.1% for tirzepatide, the company said.

In the other study, CagriSema provided a weight reduction of 21% versus 2% for a placebo, the company said. CagriSema also showed improvements compared with the placebo in other prespecified supportive endpoints including blood pressure, waist-to-height ratio, and fasting lipid profile, the company said.